Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is expected to announce its Q3 2025 earnings results before the market opens on Thursday, January 30th. Analysts expect the company to announce earnings of $0.34 per share for the quarter. Takeda Pharmaceutical has set its FY 2024 guidance at 3.330-3.330 EPS.Individual that wish to listen to the company's earnings conference call can do so using this link.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Takeda Pharmaceutical Stock Up 3.3 %
NYSE:TAK traded up $0.43 during trading hours on Thursday, reaching $13.74. The company's stock had a trading volume of 1,687,965 shares, compared to its average volume of 1,981,569. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The company has a market cap of $43.73 billion, a price-to-earnings ratio of 23.68, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical has a one year low of $12.57 and a one year high of $15.08. The business's 50-day moving average is $13.30 and its 200-day moving average is $13.89.
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
